




RealRate

PHARMACEUTICAL 2022

Spruce Biosciences INC
Rank 131 of 471

spruceBIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Spruce Biosciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spruce Biosciences INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Spruce Biosciences INC is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 357%, being 82% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	91,895
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,871
Liabilities, Non-Current	6,244
Other Assets	34,591
Other Compr. Net Income	-184
Other Expenses	345
Other Liabilities	0
Other Net Income	119
Other Revenues	0
Property and Equipment	0
Research and Development	30,698
Selling, General and Administrative Expense	11,368

Output Variable	Value in 1000 USD
Assets	126,486
Liabilities	15,115
Expenses	42,411
Revenues	0
Stockholders Equity	111,371
Net Income	-42,292
Comprehensive Net Income	-42,384
BaseVar	92,158
ECR before Limited Liability	283%
Economic Capital Ratio	357%